MapLight Therapeutics, Inc. MPLT Chemistry Manufacturing And Controls Expenses — Research And Development Expense

Other segment segments

Similar metrics at other companies

GERNChemistry, manufacturing, and control expenses — R&D

$600K-60.0%

LBR

LBRXFormulation And CMC — Direct Research And Development Expenses

$2.33M+257%

KODKAdvanced Materials And Chemicals — Research And Development Expense

$3M0.0%

GERNResearch and clinical expenses — R&D

$13M-5.1%

TYRAFacilities And Other Costs — Research And Development Expense

$1.63M+16.3%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

Questions, answered.

What is MapLight Therapeutics, Inc. 's chemistry manufacturing and controls expenses — research and development expense?

MapLight Therapeutics, Inc. (MPLT) reported chemistry manufacturing and controls expenses — research and development expense of $6.42M in Q1 2026.

How has MapLight Therapeutics, Inc. 's chemistry manufacturing and controls expenses — research and development expense changed year-over-year?

MapLight Therapeutics, Inc. 's chemistry manufacturing and controls expenses — research and development expense increased by 62.2% year-over-year, from $3.96M to $6.42M.

What does chemistry manufacturing and controls expenses — research and development expense mean?

This metric represents the portion of total research and development expenditures specifically allocated to chemistry, manufacturing, and controls (CMC) activities. It captures the costs associated with developing, scaling, and validating the manufacturing processes required to produce clinical-grade drug candidates. Monitoring these expenses provides insight into the company's investment in process optimization and supply chain readiness for its therapeutic pipeline.